AbbVie Aktie News

On April 26, AbbVie published financial results for the first quarter of 2024, which pleasantly surprised me. Rinvoq sales were about $1.1 billion in the first quarter of 2024, up 59.3% from the previous year. The company's management raised its 2024 adjusted earnings guidance from $10.97 - $11.17 to $11.13 - $11.33.

AbbVie and Johnson & Johnson have excellent dividend track records and solid businesses. However, one of these healthcare giants has a slight edge over the other.

AbbVie is an unstoppable passive income machine. Eli Lilly offers a sizzling stock performance and a growing dividend.

Drugmaker AbbVie topped sales and earnings expectations in Q1, although those expectations were modest. The leading products in its portfolio are changing quickly, which makes it difficult to determine what the future holds.

Shares of AbbVie (ABBV) slumped Friday as the pharmaceutical firm warned of deeper declines in sales of its blockbuster arthritis drug, Humira, because of competition from close copies known as biosimilars.

AbbVie Inc. (NYSE:ABBV ) Q1 2024 Earnings Conference Call April 26, 2024 9:00 AM ET Company Participants Liz Shea - Vice President of Investor Relations Rick Gonzalez - Chairman of the Board & Chief Executive Officer Rob Michael - President & Chief Operating Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Carrie Strom - Senior Vice President, AbbVie and President, Glo...

AbbVie stock was muted Friday after beating first-quarter expectations as Humira sales continue falling. Skyrizi is catching up, though.

Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q1 financial results for 2024 today. AbbVie's earnings came in at $1.37 billion, or $0.77 per share, as compared with $239 million, or $0.13 per share, in Q1 of FY23.